AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca u.S. Rare Disease (Alexion) rebates & chargebacks accrual ($M) ($M)
Form 20-F Note 19 (Inline XBRL)
Latest, FY2025
336
Period ended Dec 31, 2025
Change on a year earlier
+40.0%
240 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. Rare Disease (Alexion) rebates & chargebacks accrual ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 336 | +40.0% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 240 | +26.3% | Form 20-F FY2025 Annual Report ↗ |
| FY2023 | Dec 31, 2023 | 190 | +36.7% | Form 20-F FY2024 Annual Report ↗ |
| FY2022 | Dec 31, 2022 | 139 | – | Form 20-F FY2024 Annual Report ↗ |
Cite this data
StockData. (2026). AstraZeneca U.S. Rare Disease (Alexion) rebates & chargebacks accrual ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/gtn_accrual_us_rare
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.